SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ and Regina DEMLOVÁ. Farmakoekonomické hodnocení cetuximabu a panitumumabu v 1. linii léčby mCRC v reálné klinické praxi ČR (The Pharmacoeconomic Analysis of Cetuximab and Panitumumab in the 1st Line Treatment of mCRC in Real Clinical Practice in the Czech Republic.). Klinická onkologie. 2019, vol. 32, No 4, p. 288-293. ISSN 0862-495X. Available from: https://dx.doi.org/10.14735/amko2019288.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Farmakoekonomické hodnocení cetuximabu a panitumumabu v 1. linii léčby mCRC v reálné klinické praxi ČR
Name in Czech Farmakoekonomické hodnocení cetuximabu a panitumumabu v 1. linii léčby mCRC v reálné klinické praxi ČR
Name (in English) The Pharmacoeconomic Analysis of Cetuximab and Panitumumab in the 1st Line Treatment of mCRC in Real Clinical Practice in the Czech Republic.
Authors SEHNALOVÁ, Irena (203 Czech Republic, belonging to the institution), Barbora ŘÍHOVÁ (203 Czech Republic, guarantor, belonging to the institution), Radim NĚMEČEK (203 Czech Republic, belonging to the institution), Kateřina KINTROVÁ (203 Czech Republic, belonging to the institution) and Regina DEMLOVÁ (203 Czech Republic, belonging to the institution).
Edition Klinická onkologie, 2019, 0862-495X.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00110520
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.14735/amko2019288
Keywords (in Czech) cetuximab; panitumumab; kolorektální karcinom; analýza nákladů
Keywords in English cetuximab; panitumumab; colorectal carcinoma; cost analysis
Tags podil, rivok
Tags Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/3/2020 11:52.
Abstract
Analýza nákladů a účinnosti léčby EGFR inhibitory cetuximabem nebo panitumumabem v 1. linii metastatického kolorektálního karcinomu v České republice
Abstract (in English)
Cost and effectiveness analysis of EGFR inhibitors cetuximab or panitumumab in the first line treatment of metastatic colorectal cancer in the Czech Republic
Links
CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)
Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research
LM2015090, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 22/7/2024 16:22